Royce & Associates LP Holds Position in Heska Corporation (HSKA)

Royce & Associates LP continued to hold its stake in shares of Heska Corporation (NASDAQ:HSKA) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,000 shares of the medical research company’s stock at the end of the 2nd quarter. Royce & Associates LP owned 0.30% of Heska Corporation worth $2,143,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Victory Capital Management Inc. bought a new stake in Heska Corporation during the first quarter worth approximately $101,000. BNP Paribas Arbitrage SA raised its holdings in Heska Corporation by 1,306.0% during the first quarter. BNP Paribas Arbitrage SA now owns 1,167 shares of the medical research company’s stock worth $123,000 after purchasing an additional 1,084 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in Heska Corporation during the second quarter worth approximately $127,000. LS Investment Advisors LLC raised its holdings in Heska Corporation by 411.2% during the second quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock worth $130,000 after purchasing an additional 1,028 shares in the last quarter. Finally, Mason Street Advisors LLC bought a new stake in Heska Corporation during the first quarter worth approximately $144,000. 81.44% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Heska Corporation (HSKA) opened at 97.28 on Wednesday. The company’s 50-day moving average price is $100.25 and its 200 day moving average price is $98.61. The company has a market cap of $702.95 million, a PE ratio of 49.58 and a beta of 0.91. Heska Corporation has a one year low of $46.51 and a one year high of $115.00.

Heska Corporation (NASDAQ:HSKA) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.07. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. The business had revenue of $34.30 million for the quarter, compared to analyst estimates of $33.35 million. During the same period in the prior year, the business posted $0.35 earnings per share. Heska Corporation’s revenue was up 14.3% compared to the same quarter last year. Equities analysts forecast that Heska Corporation will post $2.04 EPS for the current fiscal year.

HSKA has been the topic of several recent analyst reports. Zacks Investment Research raised Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 target price on the stock in a report on Friday, August 4th. BidaskClub cut Heska Corporation from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Aegis initiated coverage on Heska Corporation in a report on Thursday, June 1st. They set a “buy” rating and a $114.50 target price on the stock. Benchmark Co. reissued a “buy” rating and set a $120.00 target price (up previously from $106.00) on shares of Heska Corporation in a report on Wednesday, August 9th. Finally, B. Riley reissued a “neutral” rating and set a $85.00 target price on shares of Heska Corporation in a report on Friday, July 28th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $105.20.

COPYRIGHT VIOLATION WARNING: “Royce & Associates LP Holds Position in Heska Corporation (HSKA)” was first reported by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.thestockobserver.com/2017/09/13/royce-associates-lp-holds-position-in-heska-corporation-hska.html.

In related news, EVP Nancy Wisnewski sold 825 shares of the stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $102.21, for a total value of $84,323.25. Following the transaction, the executive vice president now directly owns 38,114 shares in the company, valued at $3,895,631.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO John Mcmahon sold 2,608 shares of the stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $101.17, for a total transaction of $263,851.36. Following the completion of the transaction, the chief financial officer now owns 193 shares in the company, valued at $19,525.81. The disclosure for this sale can be found here. Corporate insiders own 14.70% of the company’s stock.

About Heska Corporation

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corporation (NASDAQ:HSKA).

Institutional Ownership by Quarter for Heska Corporation (NASDAQ:HSKA)

Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply